Drug Information Association Logo

Sunshine Act and Implications to Medical Communications

Track:
Medical Communications

Day & Time:
March 10, 3:30PM - 5:00PM

Room Number:
Ballroom Salon G

Type:
Session

Title:
Sunshine Act and Implications to Medical Communications

Chair(s):
Monica A. Kwarcinski, PharmD
Executive Director, Medical Services
Purdue Pharma L.P., United States

Description:
While the first reporting period under the Physician Payments Sunshine Act has past, industry continues to grapple with this new compliance obligation. This session will describe the obligations, challenges, and impact the Sunshine Act has had on industry medical information departments, medical science liaisons, medical writers as well as industry sponsored publications. This will be an interactive session with opportunity for discussion and questions from the audience

Learning Objective(s):
At the conclusion of this session, participants should be able to:
Describe key element of the Physician Payments Sunshine Act
Describe the specific obligations under the Sunshine Act that affect Medical Communication, Medical Science Liaisons, and Medical Writing departments within industry
Discuss examples of reprint values and the basis of those values
Identify challenges and considerations for Medical and Scientific Communications departments related to the Sunshine Act

Presentation(s) & Speaker(s):
Reporting of Reprints under the Sunshine Act: How’s it going?
Monica A. Kwarcinski, PharmD
Executive Director, Medical Services
Purdue Pharma L.P., United States

The MSL Role & Sunshine Act
Kathleen M Guindon, MS, RN
Senior Medical Science Liaison
Genentech, A Member of the Roche Group, United States

Faculty
Mina Patel
Senior Director Medical Communications, Global Medical Affairs
Vertex Pharmaceuticals Incorporated, United States

© 2014 DIA